

Angelo Azzi Zdenek Drahota Sergio Papa (Eds.)

Molecular Basis of Membrane-Associated Diseases


With 121 Figures

Springer-Verlag Berlin Heidelberg New York
London Paris Tokyo Hong Kong

Prof. Dr. ANGELO AZZI
Institut für Biochemie und Molekularbiologie
Universität Bern
Bühlstraße 28
CH-3012 Bern

Prof. ZDENEK DRAHOTA
Institute of Physiology
Czechoslovak Academy of Sciences
Videnska 1083
CS-142 20 Praha 4

Prof. SERGIO PAPA
Institute of Medical Biochemistry
and Chemistry
University of Bari
Piazza G. Cesare
I-70124 Bari



ISBN 3-540-50744-2 Springer-Verlag Berlin Heidelberg New York
ISBN 0-387-50744-2 Springer-Verlag New York Berlin Heidelberg

Library of Congress Cataloging-in-Publication Data. Molecular basis of membrane-associated diseases. Based on a symposium held in Prague on 14-16 July 1988. Includes index. 1. Cell membranes-Abnormalities-Congresses. 2. Mitochondrial membranes-Abnormalities-Congresses. 3. Lysosomal storage diseases-Congresses. I. Azzi, A. (Angelo) II. Drahota, Z. III. Papa, S. [DNLM: 1. Cell Membrane-pathology-congresses. 2. Diseases-etiology-congresses. 3. Membranes-pathology-congresses. QS 532.5.M3 M718 1988] RB152.M64 1989 616.07 89-11270

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.

© Springer-Verlag Berlin Heidelberg 1989
Printed in Germany

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Typesetting: International Typesetters Inc. Makati, Philippines
Printing: Druckhaus Beltz, Hemsbach
Binding: J. Schäffer, Grünstadt
2131/3145-543210 - Printed on acid-free paper

Contents

1 Plasma Membrane and Control of Cell Growth and Differentiation

Insulin Receptor Kinase and Insulin Action E. VAN OBBERGHEN, R. BALLOTTI, Y. LE MARCHAND-BRUSTEL and J. C. SCIMECA (With 3 Figures)	3
Structural and Functional Aspects of Signal Transduction by Receptor Tyrosine Kinases. Y. YARDEN	14
Nerve Growth Factor (NGF): Physiological Functions and Regulation of Its Synthesis. D. LINDHOLM, R. HEUMANN, G. D. BORASIO and H. THOENEN	22
Signal Transduction by Growth Factor Receptors W. H. MOOLENAAR (With 3 Figures)	29
Altered Regulation of Receptor-Associated Tyrosine Kinases in Human Tumors. P. M. COMOGLIO, M. F. DI RENZO, G. GAUDINO, S. GIORDANO, L. NALDINI and C. PONZETTO	35
The Role of Plasma Membrane Phospholipids in Cellular Pathology A. STRUNECKÁ, J. PALEČEK, L. KRPEJŠOVÁ, N. I. EL DESOUKI, P. FOLK and J. MÁCHA (With 7 Figures)	53
Changes in the Structure and Function of the Red Cell Membrane Skeleton and Hemolytic Anemias. P. JAROLIM, S.-C. LIU, TH. L. COETZER, M. LAHAV and J. PALEK (With 1 Figure)	64
Regulation of Intracellular Ca ²⁺ in Pancreatic Acinar Cells by Membrane Pumps and Channels. R. L. DORMER (With 3 Figures)	71
Control of Protein Kinase C Function by Activators and Inhibitors CH. W. MAHONEY and A. AZZI (With 2 Figures)	84

2 Regulation of Membrane Channels

K ⁺ Channels: Structure, Function, Regulation, Molecular Pharmacology and Role in Diseased States. H. BERNARDI, J.-N. BIDARD, M. FOSSET, M. HUGUES, CH. MOURRE, H. REHM, G. ROMÉY, H. SCHMID- ANTOMARCHI, H. SCHWEITZ, J. R. DE WELLES and M. LAZDUNSKI (With 9 Figures)	99
---	----

Voltage-Dependent Calcium Channels: Structure and Regulation in Normal and Abnormal States. M. M. HOSEY, F. C. CHANG, C. M. O'CALLAHAN, J. PTASIENSKI, J. BARHANIN and M. LAZDUNSKI (With 6 Figures)	112
Cell Membrane Abnormalities in Genetic Hypertension G. BIANCHI, P. FERRARI, S. SALARDI, P. SALVATI, M. FERRANDI, L. TORIELLI and B. R. BARBER	124
Transmembrane Cation Transport: An Approach to the Study of the Molecular Basis of Hypertension. L. MAZZANTI, R. A. RABINI, N. CESTER, C. ROMANINI and E. BERTOLI	130
Transmembrane Ionic Fluxes in the Brain in Energy-Depleted Cells B. K. SIESJÖ (With 9 Figures)	134

3 Mitochondrial Genetic Diseases

Mitochondrial Diseases. S. DiMAURO, A. LOMBES, H. NAKASE, M. ZEVIANI, R. RIZZUTO, C. T. MORAES and E. A. SCHON	157
Mitochondrial Myopathy: Biochemical Approaches to Respiratory Chain-Linked Electron Transfer and Energy Coupling C. P. LEE, M. E. MARTENS, P. L. PETERSON, S. H. TSANG and M. SCIAMANNA (With 6 Figures)	167
Phosphorus Magnetic Resonance Spectroscopy (³¹ P NMR) as a Tool for in Vivo Monitoring of Mitochondrial Muscle Disorders Z. ARGOV (With 5 Figures)	183
Cytochemical and Immunocytochemical Studies of Human Mitochondrial Myopathies. M. A. JOHNSON (With 7 Figures)	200
Regulatory Complexity of Cytochrome <i>c</i> Oxidase and Its Defective Manifestation in Mitochondrial Diseases. B. KADENBACH, F.-J. HÜTHER, U. BÜGE, A. SCHLERF and M. A. JOHNSON (With 7 Figures)	216
Fibroblasts and Cytochrome <i>c</i> Oxidase Deficiency D. M. GLERUM, B. H. ROBINSON and R. CAPALDI (With 2 Figures)	228
Human Cytochrome <i>c</i> Oxidase Deficiencies; Structural and Functional Aspects. K. M. C. SINJORGO, A. O. MUIJSERS, H. R. SCHOLTE, A. B. P. VAN KUILENBURG, J. J. VAN BEEUMEN, E. M. BROUWER-KELDER, J. A. BERDEN, P. A. BOLHUIS and J. M. TAGER (With 3 Figures)	239

4 Mitochondrial Metabolic Diseases

Brown Adipose Tissue, Diet-Induced Thermogenesis and Genetic Obesity. T. SOUKUP, H. RAUCHOVÁ, J. DOSOUDILOVÁ and Z. DRAHOTA (With 5 Figures)	257
--	-----

Acute and Long-Term Regulation of Brown Adipose Tissue Thermogenesis: Physiological and Pathological Implications J. HOUSTEK, J. KOPECKY, D. JANIKOVA, J. BEDNAR, M. HOLUB, T. SOUKUP, M. MIKOVÁ and K. VIZEK (With 7 Figures)	265
Molecular Composition, Fluidity of Membranes and Functional Properties of Human Liver Mitochondria and Microsomes GH. BENGA (With 3 Figures)	285
Changes in Erythrocyte and Platelet Membrane Fluidity in Childhood Obesity. G. FERRETTI, A. TANGORRA, P. L. GIORGI, M. DOTTI, G. CURATOLA and E. BERTOLI	303
Skeletal Muscle Mitochondria and Phospholipase Activity in Malignant Hyperthermia. K. S. CHEAH	309
The Antimitochondrial Antibodies (AMA) of Primary Biliary Cirrhosis (PBC). H. BAUM and M. FUSCONI	323
Toxicity, Antioxidants, and Metabolism. L. PACKER (With 3 Figures)	335

5 Cancer and Energy Metabolism

Mitochondrial H ⁺ -ATP Synthase Under Normal and Pathological Conditions. S. PAPA, F. GUERRIERI, F. ZANOTTI and F. CAPUANO (With 8 Figures)	347
Antitumor Effect of Drugs Interfering with Mitochondrial Biogenesis Š. KUŽELA, K. LUCIAKOVÁ, J. KOLAROV and B. D. NELSON (With 6 Figures)	359

6 Lysosomes and Peroxisomes in Health and Disease

The Complex of β -Galactosidase, Neuraminidase and "Protective Protein" in Lysosomes: Molecular Characterization of the "Protective Protein". A. D'AZZO, N. GILLEMANS and N. GALJART (With 5 Figures)	371
The Role of Activator Proteins in Glycolipid Degradation and Storage Diseases. E. CONZELMANN (With 3 Figures)	379
Solute Translocation Across the Lysosome Membrane: Physiology, Pathology and Pharmacology. J. B. LLOYD, T. KOOISTRA, S. FORSTER, S. J. BIRD and G. P. IVESON (With 6 Figures)	395
The Peroxisomal β -Oxidation Systems: Characteristics and (Dys) Functions in Man. R. J. A. WANDERS, C. W. T. VAN ROERMUND, M. J. A. VAN WIJLAND, R. B. H. SCHUTGENS, H. VAN DEN BOSCH and J. M. TAGER	407

Genetic Heterogeneity in Inherited Disorders with a Generalized Impairment of Peroxisomal Functions: Visualization by Immunofluorescence Microscopy of Peroxisome Assembly After Somatic Cell Fusion of Complementary Cell Lines
S. BRUL, E. A. C. WIEMER, M. OOSTHUIZEN, A. WESTERVELD, R. VAN DRIEL, A. STRIJLAND, R. B. H. SCHUTGENS, H. VAN DEN BOSCH, R. J. A. WANDERS, A. W. SCHRAM and J. M. TAGER (With 2 Figures) . . . 420

Subject Index 429

List of Contributors

You will find the addresses at the beginning of the respective contribution

- Argov, Z. 183
Azzi, A. 84
- Ballotti, R. 3
Barber, B. R. 124
Barhanin, J. 112
Baum, H. 323
Bednár, J. 265
Benga, Gh. 285
Berden, J. A. 239
Bernardi, H. 99
Bertoli, E. 130, 303
Bianchi, G. 124
Bidard, J.-N. 99
Bird, S. J. 395
Bolhuis, P. A. 239
Borasio, G. D. 22
Brouwer-Kelder, E. M. 239
Brul, S. 420
Büge, U. 216
- Capaldi, R. 228
Capuano, F. 347
Cester, N. 130
Chang, F. C. 112
Cheah, K. S. 309
Coetzer, Th. L. 64
Comoglio, P. M. 35
Conzelmann, E. 379
Curatola, G. 303
- d'Azzo, A. 371
de Weille, J. R. 99
DiMauro, S. 157
Di Renzo, M. F. 35
Dormer, R. L. 71
Dosoudilová, J. 257
Dotti, M. 303
Drahota, Z. 257
- El Desouki, N. I. 53
- Ferrandi, M. 124
Ferrari, P. 124
Ferretti, G. 303
Folk, P. 53
Forster, S. 395
Fosset, M. 99
Fusconi, M. 323
- Galjart, N. 371
Gaudino, G. 35
Gillemans, N. 371
Giordano, S. 35
Giorgi, P. L. 303
Glerum, D. M. 228
Guerrieri, F. 347
- Heumann, R. 22
Holub, M. 265
Hosey, M. M. 112
Houšťek, J. 265
Hugues, M. 99
Hüther, F.-J. 216
- Iveson, G. P. 395
- Janíková, D. 265
Jarolim, P. 64
Johnson, M. A. 200, 216
- Kadenbach, B. 216
Kolarov, J. 359
Kooistra, T. 395
Kopecký, J. 265
Krejšová, L. 53
Kužela, Š. 359

- Lahav, M. 64
Lazdunski, M. 99, 112
Lee, C.P. 167
Le Marchand-Brustel, Y. 3
Lindholm, D. 22
Liu, S.-C. 64
Lloyd, J.B. 395
Lombes, A. 157
Luciaková, K. 359
- Mácha, J. 53
Mahoney, Ch. W. 84
Martens, M.E. 167
Mazzanti, L. 130
Miková, M. 265
Moolenaar, W.H. 29
Moraes, C.T. 157
Mourre, Ch. 99
Muijsers, A.O. 239
- Nakase, H. 157
Naldini, L. 35
Nelson, B.D. 359
- O'Callahan, C.M. 112
Oosthuizen, M. 420
- Packer, L. 335
Paleček, J. 53
Palek, J. 64
Papa, S. 347
Peterson, P.L. 167
Ponzetto, C. 35
Ptasienski, J. 112
- Rabini, R.A. 130
Rauchová, H. 257
Rehm, H. 99
Rizzuto, R. 157
Robinson, B.H. 228
Romanini, C. 130
Romey, G. 99
- Salardi, S. 124
Salvati, P. 124
Schlerf, A. 216
Schmid-Antomarchi, H. 99
Scholte, H.R. 239
Schon, E.A. 157
Schram, A.W. 420
Schutgens, R.B.H. 407, 420
Schweitz, H. 99
Sciamanna, M. 167
Scimeca, J.C. 3
Siesjö, B.K. 134
Sinjorgo, K.M.C. 239
Soukup, T. 257, 265
Strijland, A. 420
Strunecká, A. 53
- Tager, J.M. 239, 407, 420
Tangorra, A. 303
Thoenen, H. 22
Torielli, L. 124
Tsang, S.H. 167
- van Beeumen, J.J. 239
van den Bosch, H. 407, 420
van Driel, R. 420
van Kuilenburg, A.B.P. 239
Van Obberghen, E. 3
van Roermund, C.W.T. 407
van Wijland, M.J.A. 407
Vížek, K. 265
- Wanders, R.J.A. 407, 420
Westerveld, A. 420
Wiemer, E.A.C. 420
- Yarden, Y. 14
- Zanotti, F. 347
Zeviani, M. 157

Nerve Growth Factor (NGF): Physiological Functions and Regulation of Its Synthesis

D. LINDHOLM¹, R. HEUMANN, G. D. BORASIO and H. THOENEN

1 Introduction

The physiological role of NGF as a neurotrophic factor in the peripheral nervous system is well established. NGF is essential for the development and maintenance of specific functions of peripheral sympathetic and neural-crest derived sensory neurons. NGF acts as a retrograde messenger between the target organs and the innervating neurons. The regionally different quantities of NGF in target tissues reflect the density of innervation by NGF-responsive neurons, which transport NGF in membrane-confined compartments to the perikaryon after NGF is bound via specific membrane receptors. Although the physiological function of NGF is well documented and a large number of NGF-specific effects on target neurons have been identified, there are two main questions which remain to be elucidated, namely the nature of the second messenger(s) evolving from the binding of NGF to its receptor and the mode of regulation of NGF synthesis in the target tissues. A better understanding of this regulation would provide the prerequisite for a rational approach to the pharmacological modification of NGF synthesis. This is of particular interest because it has recently become apparent that NGF is essential for the preservation of the function of the cholinergic neurons of the basal forebrain nuclei. These neurons are consistently affected in Alzheimer's disease and their impaired function seems to be largely responsible for the cognitive deficits of this disease.

2 Physiological Functions of NGF

Earlier work on NGF was mainly focussed on the role of NGF in embryonic development and differentiation of the peripheral nervous system (Levi-Montalcini 1987). NGF has been shown to regulate the survival of peripheral sympathetic and neural-crest derived sensory neurons during restricted periods of development (cf. Levi-Montalcini and Angeletti 1968; Greene and Shooter 1980; Thoenen and Barde 1980). This has been conclusively demonstrated in experiments on neonatal rodents where administration of anti-NGF antibodies leads to

Department of Neurochemistry, Max-Planck-Institute for Psychiatry, Am Klopferspitz 18 A.D-8033 Martinsried/Munich, FRG

¹To whom correspondence should be addressed

enhanced cell death in the NGF-responsive neuronal population, whereas exogenous NGF can rescue neurons which normally would die during the period of natural cell death. In addition, NGF is also required for differentiation and maintenance of function of the peripheral sympathetic and sensory neurons in adult life. Thus, NGF has been shown to regulate synthesis of specific enzymes which are involved in neurotransmitter production, such as tyrosine hydroxylase and dopamine β -hydroxylase as well as a series of neuron-specific peptides (cf. Otten 1984; Johnson E.M. et al. 1986; Thoenen et al. 1987). In the peripheral target fields NGF is synthesized in very low amounts and is retrogradely transported to the cell bodies of NGF-responsive neurons after being taken up via specific cell surface receptors (cf. Schwab et al. 1982). It has also been shown that the density of innervation of target organs by NGF-responsive neurons correlates with the levels of NGF and its mRNA (Korsching and Thoenen 1983; Heumann et al. 1984; Shelton and Reichardt 1984). Moreover, interruption of the retrograde axonal transport of NGF following axotomy or by pharmacological interference (e.g. colchicine treatment which results in disassembly of microtubuli) leads to degenerative changes in the NGF-responsive neurons, demonstrating that NGF acts as a retrograde messenger between the periphery and the innervating neurons (cf. Thoenen et al. 1987).

In contrast to sympathetic neurons in the peripheral nervous system, central adrenergic neurons neither respond to NGF nor carry NGF receptors (Konkol et al. 1978; Schwab et al. 1979). However, evidence for a trophic role of NGF in the central nervous system became apparent when it was shown that the cholinergic neurons of the basal forebrain nuclei express NGF receptors and exhibit specific retrograde transport of NGF (Schwab et al. 1979; Seiler and Schwab 1984). The cholinergic neurons have also been shown to respond to NGF with an increase in the levels of choline acetyltransferase (ChAT), the enzyme responsible for synthesis of the cholinergic neurotransmitter acetylcholine. This has been shown both in neonatal rats (Gnahn et al. 1983), in aggregate cultures of fetal forebrain (Honegger and Lenoir 1982), and in adult rats after partial fimbria lesions, i.e. of the septo-hippocampal connection (Hefti et al. 1984). The cell bodies of the cholinergic neurons are situated in the medial septal nuclei, in the diagonal band of Broca and in the basal nuclei of Meynert. Their fiber tracts project to the hippocampus, neocortex and olfactory bulb (cf. Cuello and Sofroniew 1984) and these innervated areas exhibit relatively high levels of NGF and NGF-mRNA as compared to other brain regions (Korsching et al. 1985; Whittemore et al. 1986; Shelton and Reichardt 1986). In analogy to the situation in the peripheral nervous system, there is a close correlation between the levels of NGF and its mRNA and the density of cholinergic innervation. Even within the rat hippocampus there are differences between NGF levels of various regions, e.g. the CA3, CA4 and dentate gyrus region have higher levels of NGF protein compared with the CA1-CA2 region and this is reflected in the density of cholinergic innervation (cf. Korsching 1986; Thoenen et al. 1987). Recent autoradiographic receptor binding studies on sections from adult rat brain have clearly demonstrated the presence of NGF receptors on these cholinergic neurons (Riopelle et al. 1987; Raivich and Kreutzberg 1987). Moreover, NGF levels and ChAT activity in rat hippocampus

increase in parallel during postnatal development, further supporting a role of NGF in this septo-hippocampal system (Auburger et al. 1987). Likewise, fimbria lesion experiments have shown that exogenous NGF administered through an infusion pump can rescue cholinergic neurons of the basal forebrain nuclei which would otherwise degenerate following the transection (Hefti 1986; Kromer 1987; Williams et al. 1986).

3 Mechanism(s) of Action of NGF

Although many actions of NGF on target neurons have been described, the overall mechanism by which NGF exerts its effects is still unknown. This also holds true for the most important long-term effect of NGF, namely its survival-promoting activity on NGF-responsive neurons. NGF receptors on sensory (Sutter et al. 1979) and sympathetic neurons (Godfrey and Shooter 1986) and on PC12 pheochromocytoma cells (Hosang and Shooter 1985) have been identified and antibodies to the NGF receptor have been produced (Chandler et al. 1984; Ross et al. 1984). Moreover, binding studies have shown the existence of both high- and low-affinity NGF receptors on target cells which are encoded by the same mRNA. However, the mechanism for conversion between the two forms is not known but the high-affinity receptor seems to be responsible for most of the biological action of NGF, at least in PC12 cells (Green et al. 1986). Recently, both human and rat NGF receptors have been cloned (Johnson D. et al. 1986; Radeke et al. 1987) and the molecular data demonstrate that the NGF receptor belongs to a novel class of membrane receptors which lack an intrinsic tyrosine kinase activity. NGF is also known not to affect neuronal proliferation which is in contrast to most growth factors which have a mitogenic activity on their target cells (cf. Thoenen et al. 1987).

Previous studies have shown that intracellular microinjection of NGF into the cytoplasm of PC12 cells, bypassing the receptor, fails to elicit differentiation which is readily seen with NGF in the culture medium (Heumann et al. 1981). Conversely, microinjected, function-blocking, anti-NGF antibodies do not inhibit NGF action on PC12 cells. These studies led to the conclusion that NGF acts by a distinct second messenger system, the nature of which remains to be elucidated (Heumann et al. 1981). The results of recent studies have suggested a role for the ras oncogene product in NGF signal transduction. Introduction of purified, activated, ras protein into PC12 cells can elicit differentiation (Bar-Sagi and Feramisco 1985), and microinjected, anti-ras antibodies are able to block the effect of NGF on these cells (Hagag et al. 1986). The exact site of action of ras or of ras-like proteins in the signal transduction cascade induced by NGF is not known. Further downstream, transcriptional activators are most probably involved in regulating NGF-specific gene expression. Interestingly, NGF (Greenberg et al. 1985) as well as ras protein (Stacey et al. 1987) are known to transiently increase expression of the c-fos proto-oncogene product which is thought to be involved in transcriptional regulation. Milbrandt (1987) has recently described another putative transcriptional activator gene whose transcription is strongly induced in PC12 cells by short-term NGF treatment.

4 Regulation of NGF Synthesis and Implications for Treatment of Alzheimer's Disease

In Alzheimer's disease the cholinergic neurons of the basal forebrain nuclei are consistently affected and there is an atrophy and/or loss of these neurons during the course of this disease (Coyle et al. 1983; Pearson et al. 1983). Moreover, the impaired synthesis of acetylcholine is one of the earliest detectable signs of Alzheimer's disease and correlates well with the cognitive deficits observed (Francis et al. 1985). In view of the fact that these cholinergic neurons are also the target of NGF in the central nervous system, the hypothesis was put forward that NGF could play a role in this disease (Hefti and Weiner 1986). The idea that Alzheimer's disease results from an insufficient supply of NGF for these neurons has recently been disputed by Goedert and co-workers (1986). These authors demonstrated that the levels of NGF-mRNA in the cerebral cortex of patients with Alzheimer's disease are not different from the corresponding levels found in age-matched controls. Nevertheless, the following observations support the notion that pharmacological amounts of NGF are of potential value in treatment of Alzheimer's disease by supporting the cholinergic neurons undergoing atrophy or degeneration. Thus, it has been demonstrated that chronic administration of NGF over a period of 4 weeks can improve memory function, as shown by behavioural tests, and can counteract cholinergic cell body atrophy observed in a subpopulation of aged rats (Fischer et al. 1987). Moreover, studies on septo-hippocampal lesions clearly show that exogenous NGF has a beneficial effect in preventing cholinergic cell degeneration in the septal area after a transection of the fimbria (Hefti 1986; Kromer 1987; Williams et al. 1986). Likewise, NGF injections (Will and Hefti 1985) or transplantation of fetal cholinergic neurons into the hippocampus (Dunnett et al. 1982; Gage and Björklund 1986) can improve both learning and memory deficits observed in rats after such a lesion.

In view of these findings it seems justified to consider NGF supplementation as a possible therapeutic approach for the treatment of patients suffering from Alzheimer's disease. This could be achieved by either local administration of recombinant human NGF, of peptides with NGF-like functions or by enhancing endogenous NGF synthesis by pharmacological agents. However, a prerequisite for such an intervention is a better understanding of the physiological mechanisms by which NGF is regulated *in vivo*. Recent studies in the peripheral nervous system have shown that specific polypeptide factors are involved in the control of NGF synthesis in the nonneuronal cells. Using the rat sciatic nerve as a model system under conditions of degeneration and regeneration after a nerve lesion, we were able to show that macrophages play an important role in NGF regulation (Heumann et al. 1987; Thoenen et al. 1988). Interleukin-1, a lymphokine produced by these cells, was found to be the responsible agent increasing NGF-mRNA levels in the nonneuronal cells (Lindholm et al. 1987). Recent studies indicate that the action of IL-1 involves activation of phospholipase A2 and that IL-1 has a dual effect on NGF-mRNA. Thus, IL-1 enhances NGF gene transcription and also increases the stability of NGF-mRNA in cultured sciatic nerve fibroblasts (Lindholm et al. 1988).

The studies on the regulation of NGF synthesis in the central nervous system are less advanced compared with the peripheral nervous system. We have recently obtained evidence that IL-1 and other mesenchymal growth factors can influence NGF-mRNA levels in cultured rat astrocytes. We are currently studying the complex interplay of various growth factors in controlling NGF-mRNA synthesis in the central nervous system both in vivo and in vitro. Moreover, since it has very recently been reported that hippocampal neurons can also express NGF-mRNA (Rennert and Heinrich 1986; Ayer-LeLievre et al. 1988) this adds a new dimension to studies concerned with the regulation of NGF synthesis in the central nervous system.

References

- Auburger G, Heumann R, Hellweg R, Korsching S, Thoenen H (1987) Developmental changes of nerve growth factor (NGF) and its mRNA in the rat hippocampus: comparison with choline acetyltransferase. *Dev Biol* 120:322-328
- Ayer-LeLievre C, Olson L, Ebendal T, Seiger A, Persson H (1988) Expression of the β -nerve growth factor gene in hippocampal neurons. *Science* 240:1339-1341
- Bar-Sagi D, Feramisco JR (1985) Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. *Cell* 42:841-848
- Chandler CE, Parson LM, Hosang M, Shooter EM (1984) A monoclonal antibody modulates the interaction of nerve growth factor with PC12 cells. *J Biol Chem* 259:6882-6889
- Coyle JT, Price DL, de Long MR (1983) Alzheimer's disease: a disease of cortical cholinergic innervation. *Science* 219:1184-1189
- Cuello AC, Sofroniew MV (1984) The anatomy of the CNS cholinergic neurons. *Trends Neurosci* 7:74-78
- Dunnett SB, Low WC, Iversen SD, Stenevi U, Björklund A (1982) Septal transplants restore maze learning in rats with fornix-fimbria lesions. *Brain Res* 251:335-348
- Fischer W, Victorin K, Björklund A, Williams LR, Varon S, Gage FH (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. *Nature (London)* 329:65-68
- Francis PT, Palmer AM, Sioms NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK (1985) Neurochemical studies of early-onset Alzheimer's disease. Possible influence of treatment. *Lancet* 4:7-11
- Gage FH, Björklund A (1986) Cholinergic septal grafts into hippocampal formation improve spatial learning and memory in aged rats by an atropine-sensitive mechanism. *J Neurosci* 6:2837-2847
- Gnahn H, Hefti F, Heumann R, Schwab M, Thoenen H (1983) NGF-mediated increase of choline acetyltransferase (CHAT) in the neonatal forebrain: evidence for a physiological role of NGF in the brain? *Dev Brain Res* 9:45-52
- Godfrey EW, Shooter EM (1986) Nerve growth factor receptors on chick embryo sympathetic cells: binding characteristics and development. *J Neurosci* 6:2543-2550
- Goedert M, Fine A, Hunt SP, Ullrich A (1986) Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. *Mol Brain Res* 1:85-92
- Green SH, Rydel RE, Connolly JL, Greene LA (1986) PC12 mutants that possess low- but not high-affinity nerve growth factor receptors neither respond to nor internalize nerve growth factor. *J Cell Biol* 102:830-843
- Greenberg ME, Greene LA, Ziff EB (1985) Nerve growth factor and epidermal growth factor induce rapid transient changes in proto-oncogene transcription in PC12 cells. *J Biol Chem* 260:14101-14110
- Greene LA, Shooter EM (1980) The nerve growth factor: biochemistry, synthesis and mechanism of action. *Annu Rev Neurosci* 3:353-402

- Hagag N, Halegoua S, Viola M (1986) Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21. *Nature (London)* 319:680-682
- Hefti F (1986) Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transections. *J Neurosci* 6:2155-2162
- Hefti F, Weiner WJ (1986) Nerve growth factor and Alzheimer's disease. *Ann Neurol* 20:275-281
- Hefti F, Dravid A, Hartikka J (1984) Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with septo-hippocampal lesions. *Brain Res* 293:305-311
- Heumann R, Schwab M, Thoenen H (1981) A second messenger required for nerve growth factor biological activity? *Nature (London)* 292:838-840
- Heumann R, Korsching S, Scott J, Thoenen H (1984) Relationship between levels of nerve growth factor (NGF) and its messenger RNA in sympathetic ganglia and peripheral target tissues. *EMBO J* 3:3183-3189
- Heumann R, Lindholm D, Bandtlow C, Meyer M, Radeke MJ, Misko TP, Shooter E, Thoenen H (1987) Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration and regeneration: role of macrophages. *Proc Natl Acad Sci USA* 84:8735-8739
- Honegger P, Lenoir D (1982) Nerve growth factor (NGF) stimulation of cholinergic telencephalic neurons in aggregating cell cultures. *Dev Brain Res* 3:229-239
- Hosang M, Shooter EM (1985) Molecular characteristics of nerve growth factor receptors on PC12 cells. *J Biol Chem* 260:655-662
- Johnson D, Larahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M (1986) Expression and structure of the human NGF receptor. *Cell* 47:545-554
- Johnson EM Jr, Rich KM, Yip HK (1986) The role of NGF in sensory neurons in vivo. *Trends Neurosci* 1:33-37
- Konkol RJ, Mailman RB, Bendeich EG, Garrison AM, Mueller RA, Breese GR (1978) Evaluation of the effects of nerve growth factor and anti-nerve growth factor on the development of central catecholaminergic neurons. *Brain Res* 144:277-285
- Korsching S (1986) Nerve growth factor in the central nervous system. *Trends Neurosci* 11/12:570-573
- Korsching S, Thoenen H (1983) Nerve growth factor in sympathetic ganglia and corresponding target organs of the rat: correlation with density of sympathetic innervation. *Proc Natl Acad Sci USA* 80:3513-3516
- Korsching S, Auburger G, Heumann R, Scott J, Thoenen H (1985) Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. *EMBO J* 4:1389-1393
- Kromer LF (1987) Nerve growth factor treatment after brain injury prevents neuronal death. *Science* 235:214-216
- Levi-Montalcini R (1987) The nerve growth factor: thirty-five years later. *EMBO J* 6:1145-1154
- Levi-Montalcini R, Angeletti PU (1968) Nerve growth factor. *Physiol Rev* 48:534-569
- Lindholm D, Heumann R, Meyer M, Thoenen H (1987) Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. *Nature (London)* 330:658-659
- Lindholm D, Heumann R, Hengerer B, Thoenen H (1988) *J Biol Chem* 263:16348-16351
- Milbrandt J (1987) A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. *Nature (London)* 238:797-799
- Otten U (1984) Nerve growth factor and the peptidergic sensory neurons. *Trends Pharmacol* 7:307-310
- Pearson RCA, Sofroniew MV, Cuello AC, Powell TPS, Eckenstein F, Esiri MM, Wilcock GK (1983) Persistence of cholinergic neurons in the basal nuclei in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. *Brain Res* 289:375-379
- Radeke MJ, Misko TP, Hsu C, Herzenberg LA, Shooter EM (1987) Gene transfer and molecular cloning of the rat nerve growth factor receptor: a new class of receptors. *Nature (London)* 325:593-597
- Raivich G, Kreutzberg GW (1987) The localization and distribution of high affinity β NGF binding sites in the central nervous system of the adult rat. A light microscopic autoradiographic study using (125I) β NGF. *Neuroscience* 20:23-36
- Rennert PD, Heinrich G (1986) Nerve growth factor mRNA in brain: localization by in situ hybridization. *Biochem Biophys Res Commun* 138:813-818

- Riopelle RJ, Verge VMK, Richardson PM (1987) Properties of receptors for nerve growth factor in the mature rat nervous system. *Mol Brain Res* 3:45–53
- Ross AH, Grob P, Bothwell M, Elder DE, Ernst CS, Marano N, Ghrist BFD, Slemp CC, Herlyn M, Atkinson B, Koprowski H (1984) Characterization of nerve growth factor receptor in neural crest tumours using monoclonal antibodies. *Proc Natl Acad Sci USA* 81:6681–6685
- Schwab M, Otten U, Agid Y, Thoenen H (1979) Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra. *Brain Res* 168:473–483
- Schwab ME, Heumann R, Thoenen H (1982) Communication between target organs and nerve cells: retrograde axonal transport and site of action of nerve growth factor. *Cold Spring Harbor Symp Quant Biol* 46:125–134
- Seiler M, Schwab ME (1984) Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. *Brain Res* 300:33–39
- Shelton DL, Reichardt LF (1984) Expression of the nerve growth factor gene correlates with the density of sympathetic innervation in effector organs. *Proc Natl Acad Sci USA* 81:7951–7955
- Shelton DL, Reichardt LF (1986) Studies on the expression of the β nerve growth factor (NGF) gene in the central nervous system: level and regional distribution of NGF mRNA suggest that NGF functions as a trophic factor for several distinct populations of neurons. *Proc Natl Acad Sci USA* 83:2714–2718
- Stacey DW, Watson T, Kung H-F, Curran T (1987) Microinjection of transforming ras protein induces c-fos expression. *Mol Cell Biol* 7:523–527
- Sutter A, Riopelle RJ, Harris-Warrick RM, Shooter EM (1979) Nerve growth factor receptors: characterization of two distinct classes of binding sites on chick embryo sensory cells. *J Biol Chem* 254:5972–5982
- Thoenen H, Barde Y-A (1980) Physiology of nerve growth factor. *Physiol Rev* 60:1284–1335
- Thoenen H, Bandtlow C, Heumann R (1987) The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. *Rev Physiol Biochem Pharmacol* 109:145–178
- Thoenen H, Bandtlow C, Heumann R, Lindholm D, Meyer M, Rohrer H (1988) Nerve growth factor: cellular localization and regulation of synthesis. *Cell Mol Neurobiol* 8:35–40
- Whittemore SR, Ebendal T, Lärkfors L, Olson L, Seiger A, Strömberg I, Persson H (1986) Developmental and regional expression of β nerve growth factor messenger RNA and protein in the rat central nervous system. *Proc Natl Acad Sci USA* 83:817–821
- Will B, Hefti F (1985) Behavioural and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions. *Behav Brain Res* 17:17–24
- Williams LR, Varon S, Peterson GM, Victorin K, Fischer W, Björklund A, Gage FH (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. *Proc Natl Acad Sci USA* 83:9231–9235

Subject Index

- Abelson murine leukemia virus (AMuLV) 38
Acetylcholine 71, 73
Acute lymphoblastic leukemia (ALL) 39, 41
Acyl-CoA oxidase deficiency 411
Adducin 126
Adiposity 257
Adrenoleukodystrophy (NALD) 420
Alkoxy radicals 336
Aminoacridines 90
3,4-aminopyridines 104
Amylase 73
Ankyrin-band 3 interaction 65
Anoxia
 changes in extracellular ion concentrations 137
 suddenly occurring 137
 terminal depolarization 137
Antibodies
 antimitochondrial (AMA) 323-334
 reactivity with bacteria 328
 phosphotyrosine 37
Antioxidants 335-343
Antitumor drugs 359-367
Apamin receptor 102
 expression during brain ontogenesis 102
 sensitive channels 102
Arachidonic acid 286, 289
Arylsulfatase 379
ATPase (Ca²⁺) activation by calmodulin 76
ATPase
 (Ca²⁺, Mg²⁺) activated 71
 activated by Ca²⁺ 75
ATP synthase 347-358
 and neoplasia 350
 during liver regeneration 351
Au-S-malate 90
Auranofin 90
 inhibition of neutrophil NADPH oxidase 90
Autocrieny 35, 41, 44
Autoerythrocyte sensitization syndrome 53
Autosensitization
 against patient red blood cells 53
 antibodies against mitochondria (AMA) 323
 circulating antibodies against Ca channels 120
 pathogenesis 53
 PS as a provocative factor 53
 α -tocopherol *see* Vitamin E
 α -tocopherylquinone 91
 α -₁ peptide 113
 sequence homology to voltage-dependent Na channels 114
 substrate for protein kinase C 118
Bcr-abl 38
 tyrosine kinase 40
Biliary diseases 299
Bombesin 29, 31, 42-45
 growth factor 41
 in growth control 42
 in small-cell lung carcinomas
 mitogenic 42
 trigger for tyrosine kinase 42
Bradykinin 30, 32
Brown adipose tissue 257-264, 265-284
 acute regulation 270
 biogenesis 275
 deiodinase activity 270
 hyperfunction 277
 in diabetic obese (db/db) mice 276
 in genetic obesity 276
 in heat production 266
 in myopathic hamsters 269
 in nude mouse 278
 in pathological states 276
 in the febrile response 277
 ligands of uncoupling protein 271
 malfunction 277
 mitochondria 259
 morphological data
 perinatal development 266, 272
 regulation 266, 270
 thermogenetic function 257
 β -carotene 338
 β -cell 104
 β -D-galactosidase 371
 β -hexosaminidase A 380
C-abl gene 39
C-abl protein 39
 structural alteration 40
C-erb-B2 46, 47
C-fms 47
C-fos 24
C-kit 47

- C-met 47
 C-onc proteins 47
 C-trk 46, 47
 Ca²⁺
 activated photoproteins 72
 activation of K⁺ channel 75, 99
 free cytoplasmic concentration 77
 GTP induced Ca²⁺ release 78
 indicators 72
 influx inhibited by antimycin A 74
 inhibition of cell entry 74
 ionophores 72
 iontophoresis 72
 mechanism of cell entry 74
 movements in pancreatic acinar cells 73
 release
 induced by Ca²⁺ 78
 induced by Ins(1,4,5)P₃ 78
 occurs in discrete organelles 78
 stimulated by GTP 78
 store 77
 Ca²⁺ channels
 antagonists
 competitive (AP7) 143
 non-competitive (MK801) 143
 of the dihydropyridine type 143
 antibodies and autoimmune disease 120
 effectors 113
 in excitable and nonexcitable cells 112
 L-type
 in disease 119
 increased in cardiomyopathic hamsters 119
 regulation by phosphorylation 117
 voltage-dependent 112, 141
 purification and characterization 113
 Calcineurin 117
 Calciosomes 78
 Calsequestrin 78
 Carcinoma cells 30
 Cerebral metabolic rate 134
 Cerebro-hepato-renal (Zellweger)
 syndrome 420
 Cholecystokinin 71
 Chronic myelogenous leukemia (CML) 38
 Chronic progressive external ophthalmoplegia
 (CPEO) 224
 Cinnarizine 74
 Cl⁻/HCO⁻³ antiporter 145
 Cl⁻ channels
 control by membrane potential 72
 in the apical membrane 72
 Class 1 oncogenes 36, 37
 intracellular targets 37
 Class 2 oncogenes 37
 CML 39
 Cold adaptation 265
 Complementation analysis 420
 Complex IV 216
 CPEO 200, 206
 Creatine kinase (CK) 186
 CSF-1 15
 CSF-1-R 14
 Cystinosis 403
 Cytochrome *c* 298
 Cytochrome *c* oxidase 218, 228, 240, 260, 297, 360
 deficiencies 216-226, 228-236, 239-250
 clinical heterogeneity 244
 encephalomyopathies 245
 in CPEO 245
 in human 239
 infantile myopathies 244
 lack of specific subunit 248
 ophthalmoplegia 245
 type-A 246
 type-B 247
 differences in the small subunits 243
 different gene families 221
 from rat brown fat tissue 220
 immunocytochemical studies 207
 immunopurified from muscle biopsies 246
 isoenzymes 243
 microphotometric assay 207
 nuclear and mitochondrial genome
 products 228
 subunits 240
 from adult and fetal tissues 219
 specific antisera 224
 tissue-specific isoenzymes 241
 D-2-amino-phosphonoheptanoate
 D-2-amino-phosphonovalerate (AP5)
 DAG (*see also* diacylglycerol) 85
 activation of protein kinase C 87
 Dantrolene 317
 DCCD-binding protein 347
 Deiodinase 268
 catecholamine-induced activation 269
 type I and II 268
 Dendrotoxins 108
 Diacylglycerol (DAG) 30, 58, 61, 73
 1,4-dihydropyridine (DHP) 113
 DPH-as fluorescent probe 306
 Duchenne dystrophy 194
 EGF (epidermal growth factor) 16, 29, 38,
 44-46
 chemical crosslinking 16
 intermolecular activation 16
 microaggregation 16
 monomeric and dimeric forms 16
 signal transduction 17
 Electron transfer 177
 Elliptocytosis (hereditary) 66
 Encephalomyelopathy 161
 Energy metabolism 135
 progressive reduction 136

- Epidermal growth factor (*see* EGF) 29
- Epilepsy with ragged red fibers (*see also* MERRF) 159
- Erb-B 14
 oncogene 29
- Exocytosis 72
- Fabry disease 388
- Fatal infantile mitochondrial myopathy 161, 229
- Fluorescence polarization 307
- F-met-leu-phe 89
- Free oxygen radicals 300
- Galactosialidosis 372, 373
- Galanin 105
- Ganglioside GM3 390
- Gastric carcinoma 44
- Gaucher disease 387
- Genetically dysgenic mouse mdg/mdg 119
 lack of receptor for Ca²⁺ channel effectors 119
- Glibenclamide 104
- Glutathione 340
- Glutathione peroxidase 341
- Glycolipid catabolism 382
- Glycosphingolipids 379
- Gold-type antirheumatic drugs 90
- GM₂ activator 380, 382
- G-proteins 32
- Growth factors 14
 bombesin 41
 EGF 16
 chemical crosslinking 16
 intermolecular activation 16
 microaggregation 16
 monomeric and dimeric forms 16
 signal transduction 17
 hemopoietic growth factor CSF-1 35
 NGF 22-28
 and cholinergic neurons 23
 antibodies 24
 as a neurotrophic factor 22
 in Alzheimer's disease 25
 insufficient supply 25
 intracellular microinjection 24
 levels of choline acetyltransferase (ChAT) 23
 macrophages role in regulation 25
 mechanism(s) of action 24
 nature of the second messenger(s) 22
 pharmacological modification 22
 physiological function 22
 preventing cholinergic cell degeneration 25
 regional distribution 22
 regulation of synthesis 23
 required for differentiation 23
 response 23
 retrograde axonal transport 23
 trophic role 23
 PDGF 14, 29, 37, 38, 44, 46
- H-9 88
- Heinz bodies 67
- Hemichromes 67
- Hemolytic anemia
 effect of hemoglobin denaturation 67
 microangiopathy 66
 spectrin mutants 66
 transfusion-dependent 66
- Hemopoietic malignancies 38
- Hereditary spherocytosis 57
- Histamine 30, 32
 human HeLa cells growth 31
- Human fibroblasts 44
- Hydrogen peroxide 336
- Hydroxyl radicals 337
- Hypermetabolism of non-thyroid origin 167
- Hyperphagia 258
- Hypertension 124-128, 129-132
 defects in Na⁺ transport 130
 essential
 animal model 124
 Na⁺, K⁺ ATPase activity 131
 pregnancy-induced (PIH) 130
- Hypoglycemia 146
 coma 134
 ionic gates involved 140
 preischemic 139
- Inflammation and cancer 337
- Inositol phospholipids 29, 30
- 1,4,5-inositol triphosphate (*see also* IP₃) 58
- Insulin 3-13, 44, 45
 antibodies 3
 binding and kinase activation 4
 dose-response 4
 metabolic and growth-promoting effects 10
 phosphorylating cellular substrates 5
 receptor 17
 antiphosphotyrosine antibodies 6
 autophosphorylation 6
 chimeric constructions 17
 domains 17
 heterodimers 17
 kinase hyperactivity 6
 kinase impairment 6
 ligand-induced kinase activation 17
 mutation 7
 phosphorylation 3
 phosphorylation reversibility 6
 seryl (and threonyl) phosphorylation 8
 specificity of effects 6
 structure 3
 tyrosine kinase 4

- release 104
 - tolbutamide and sulfonylurea 104
 - sensitive protein kinase 3
 - transmembrane signalling 3
- Interleukin-1 25
- Ionophore (A 23187) 58
 - and phosphatidylinositol 4-phosphate 59
- IP₃ (Inositol-1,4,5-trisphosphate) 30, 61, 75, 77, 85
- IP₄ (Inositol-1,3,4,5-tetraphosphate) 75
- K⁺ channels 57, 99-110, 105
 - ATP-regulated 104
 - opened by galanin 105
 - presence in cardiac cells 105
 - presence in neurons 105
 - sulfonylureas block 104
 - Ca²⁺-activated 99
 - TEA (tetraethylammonium) block 99
 - voltage-dependent 107
- Kearns-Sayre syndrome (KSS) 159, 200, 206, 223
 - age of onset of clinical symptoms 201
 - with lacticacidemia (Robinson) 229
- Ketamine 149
- Kidney cross-transplantation 125
- KSS *see* Kearns-Sayre syndrome
- Lambert-Eaton myasthenic syndrome 120
- Leigh's disease (subacute necrotizing encephalomyelopathy) 157, 161, 200
- Liver regeneration 350
- Long-term potentiation 108
- Loose coupling 157
- Luft disease 158
- Lung cancer
 - incidence 338
- Lysosomes 381, 395-406
 - carriers for neutral amino acids 399
 - entry of dipeptides 399
 - hydrolases 381
 - inborn errors 402
 - membrane permeability 395
 - metabolite-porters 399
 - passive diffusion 398
 - storage disease 381
- Lysosphingolipids 90
- Magnetic resonance spectroscopy (*see also* NMR and ³¹P-NMR) 183
- Malignant hyperthermia (MH) 309-322
- Malignant hyperthermia
 - ATPase activity 313
 - Ca²⁺ accumulation 310
 - Ca²⁺ release 316
 - Ca²⁺ transport 310
 - halothane 310
 - in healthy pigs 309
 - phospholipase A 309
 - phospholipase A₂ activity 314
 - uncoupling of oxidative phosphorylation 310
- Malignant transformation 14
- M antigens 324
- M₂ antigen 328
 - identity with 70 kD antigen 329
 - non-mitochondrial location 329
- Mast cell degranulating peptide 107
- McArdle's syndrome 192
- MELAS (mitochondrial encephalomyopathy with lactic acidosis) 159, 223
 - in complex I deficiency 159
- Membrane fluidity 285-302, 303-308
- MERFF syndrome 161, 202, 223
 - transmission by maternal inheritance 159
- Merocyanine-540 54
 - binding in homologous RBC 54
- Metachromatic leukodystrophy (MLD) 388
- Microcytoma 41
- Milan hypertensive rat strain (MHS) 124
- Mitochondria
 - abnormal 189
 - assays of preparations 170
 - content of respiratory chain carriers 170
 - diseases 157
 - enzyme defects
 - benign infantile myopathy 161
 - complex I 160
 - complex II 160
 - complex IV 161
 - CPT deficiency 159
 - cytochrome *c* oxidase (COX) 161
 - cytochrome *c* oxidase deficiency 167
 - different genetic errors 161
 - fatal infantile myopathy 161
 - Krebs cycle 160
 - Leigh syndrome 161
 - MERRF syndrome 161
 - oxidation-phosphorylation coupling 160
 - respiratory chain 160
 - spontaneous mutation of mtDNA 161
 - substrate utilization 159
 - fragment preparation 168
 - in cancer chemotherapy 365
 - lipid composition 286
 - membranes amino acid composition 290
 - fluidity probed by spin labeling 291
 - protein-lipid interactions 291
 - morphological abnormalities 201
 - myopathies 167-180, 183-189, 200-214, 223
 - abnormal morphological features 228
 - cytochrome measurement 234
 - defect
 - characterization 232
 - cytochrome *c* oxidase 231
 - fibroblasts as diagnostic tools 230

- immunodetection 232
- lactate to pyruvate ratio (L/P) 231
- lactic acidosis 229
- maternal inheritance 239
- maternal transmission 212
- northern analysis 235
- subunit specific antisera 230
- with encephalopathy 159
- partial reactions of the respiratory chain 170
- preparations 168
 - from Kearns-Sayre syndrome tissues 171
 - semimicro-techniques 178
- respiratory functions 310
- tightly coupled, from skeletal muscle 171
- transformation into thermogenic 275
- Mitochondrial encephalomyopathy with lactic acidosis (*see also* MELAS) 159
- Morris hepatoma 3924A 351
- Muscular dystrophy 194
- Myopathies
 - megaconial 157
 - mitochondria 187, 200
 - carnitine palmitoyltransferase (CPT) deficiency 157
 - enzyme defects
 - complex I 200
 - complex III 200
 - complex IV 200
 - major gene deletions 158
 - microphotometric assays 200
 - morphological classification criteria 157
 - NADH-coenzyme Q reductase 188
 - ³¹P nuclear magnetic resonance (NMR) spectroscopy 158
 - ragged red fibers, RRF 157
 - reduction in post-exercise recovery of PCr 187
 - steroid experimental therapy 195
 - vitamins K₃ (menadiione) therapy 194
 - pleoconial 157
- Myotonic muscle dystrophy 102

- N-acetyl- α -neuraminidase (sialidase) 371
- Na⁺ channel 99
 - sensitivity to apamin 99
- Na⁺ retention in MHS 125
- Na⁺/Ca²⁺ exchange 71, 76
- Na⁺/H⁺ antiporter 145
- Na⁺/H⁺ exchange
 - activation of 32
 - amiloride-sensitive 32
 - deactivation 33
 - differentiation process 33
- NADH-dehydrogenase (complex I) 25
- Neoplastic cell markers 37
- Neu . 15
- Neuroblastoma 89
- Neurohormone 42

- NGF (nerve growth factor) 25
 - and cholinergic neurons 23
 - antibodies 24
 - in Alzheimer's disease 25
 - insufficient supply 25
 - intracellular microinjection 24
 - level of choline acetyltransferase (ChAT) 23
 - macrophages role in regulation 25
 - mechanism(s) of action 24
 - nature of the second messenger(s) 22
 - pharmacological modification 22
 - physiological function 22
 - preventing cholinergic cell degeneration 25
 - regional distribution 22
 - response 23
- Nifedipine 74
- NMR 183
 - ATP concentration 184
 - determination of intracellular pH 183
 - isolated heart mitochondria in vitro 185
 - phosphocreatine (PCr) and inorganic phosphates (P_i) detection 183
 - spectroscopy 158
- Obesity 257
 - genetic forms
 - db/db mouse 258
 - ob/ob mouse 258
 - synthesis and turnover of cholesterol 303
- Omega-phosphonic acid 143
- Oncogenes (*see also* specific oncogenes)
 - class -2 35
 - coded tyrosine kinases 36
 - control of cell proliferation 36
 - tyrosine phosphorylation 36
- Organic hydroperoxides 336
- Oxidative phosphorylation 134, 216, 359
 - in rapidly growing tumors
 - respiratory chain-linked 176
 - uncoupling 266
- Oxytetracycline 362

- P₁₄₅ 44
 - biological functions 45
 - dephosphorylation 46
 - in liver cells 46
 - tyrosine phosphorylation 45
- Pancreatic acinar cell 71
- PCr/P_i 190
 - age-related reduction 194
 - at rest 193
 - carnitine deficiency 190
 - in acute disorders 195
 - in chronic polymyositis 194
 - in resting muscle PCr/P_i 195
 - malignant hyperthermia 190
 - non specificity for primary mitochondrial diseases 196

- recovery
 - after exercise 193
 - in myophosphorylase deficiency 192
- PDGF 37, 38, 44, 46
- Peroxisomes 407
 - β -oxidation 407-419
 - energetic aspects 410
 - inborn errors 411
 - induction 410
 - in detoxification reactions, serving 415
 - inherited disorders 420-428
 - in mammalian metabolism 407
 - physiological importance 407
 - thiolase deficiency 411
 - visualization by indirect immunofluorescence 423
- Phenylalkylamines (PAA) 113
- Philadelphia chromosome 38
- Phorbol esters 33, 73
- Phosphatidylethanolamine (PE) 53
- Phosphatidylinositol 4,5-bisphosphate (PIP₂) 58
- Phosphatidylserine (PS) 53
- Phosphatidylserine reaction with TNBS 54
- Phosphoinositide signalling system 58
- Phospholipase C 29, 73
- Phospholipids
 - asymmetry 53, 54
 - plasma membrane 53
 - reaction of RBC with TNBS 55
- Phosphorylation potential (PP) 186
- Phosphotyrosine antibodies 37
- Plasma
 - abnormalities in hypertension 124-128
 - lipids 304
 - thermolabile factor 56
- ³¹P-NMR 183-198
 - indicators of mitochondrial disease 189
 - monitoring of therapy 194
 - spectrum of muscle at rest 183
- Primary biliary cirrhosis (PBC) 323-334
 - antimitochondrial antibodies (AMA) 323
 - cross-reacting epitopes 332
 - oxygen-free radicals (oxidants) 335
 - pathogenesis 332
- Progressive external ophthalmoplegia (*see also* CPEO) 200
- Protective protein 371-378
 - cDNA 373
- Protein kinase C 30, 38, 58, 73, 84-94, 127
 - α , β and γ forms 85
 - activation of 31, 84, 85
 - by aplysiatoxin 87
 - by DAG 87
 - by lead 87
 - by phorbol diesters 87
 - by teleocidin 87
 - by tumor promoters 87
 - by unsaturated fatty acids 86
 - and EGF receptor phosphorylation 86
 - apparent molecular weight 84
 - auto-phosphorylation of α and γ forms 86
 - differential distribution in brain 85
 - in human neutrophils 85
 - in normal and ras-transformed 3T3 fibroblasts 85
 - inhibitors 88, 90
 - affecting Ca²⁺ binding 88
 - affecting the site of interaction with the protein substrate 88
 - platelet aggregation 89
 - redistribution 85
 - regulatory domain 86
 - preparation by tryptic digestion 86
 - substances affecting 89
 - respiratory burst of neutrophils 89
- Protein transport 364
- Proton conductivity 353
- Pseudogenes 223
- Pyropoikilocytosis 66
- Quin 2 72
- Ragged-red fibers 201, 223
- Ras 24
- Ras-like proteins 24
- RBC (red blood cells)
 - cytoskeleton 55
 - visualization in human cells 55
 - merocyanine 540 binding 55
 - phospholipids reaction with TNBS 55
 - presence of tubulin and actin 55
 - tubulin in human cells 55
- Receptors
 - aggregation 18
 - and channel regulation 112
 - autoregulation 37
 - bombesin complex in small-cell lung carcinomas 43
 - cellular activation 18
 - collision-coupling 18
 - dimerization 18
 - EGF 16
 - for apamin 102
 - G-protein coupled 15
 - glutamate 142
 - activation
 - kainate (K) 142
 - N-methyl-D-aspartate (N or NMDA) 142
 - quisqualate (Q) 142
 - growth factors 29-34
 - lacking tyrosine kinase activity 24
 - monoclonal and polyclonal antibodies 18
 - PDGF 45
 - photoaffinity labelling 113

- signal transduction by EGF 16
 tyrosine kinase 14-21, 32, 35-52
 tyrosine kinases (RTK's) 14
 Red blood cell (*see also* RBC) 53
 membrane skeleton 64
 stability and oxidant damage 67
 Renal transplant rejection 67
 Respiratory burst of neutrophils 89
 Respiratory chain 239
 abnormalities 210
 tissue-specific isoforms of enzymes 212
 Respiratory control ratio (RCR) 353
 Retroposons 222
 Retropseudogenes 223
 Ros 15
 RTK
 overexpression 14
 signal transduction 15

 Salla disease 400
 Sandhoff disease 383
 Secretion of digestive enzymes
 intracellular Ca^{2+} as a regulator 72
 Sickle cells 57
 Spectrin 61, 64
 abnormalities of molecule 65
 hemolytic anemia 66
 mutants 66
 Sphingosine 90
 Staurosporine 88, 89
 N-propan-2-ol- and N-phenyl-derivatives 88
 Steinert disease 102
 Storage diseases 379-394
 Subacute necrotizing encephalomyelopathy
 (Leigh's disease) 229
 Substance P 29
 Sulfatide activator 386
 in glycolipid catabolism 387
 Superoxide dismutase 341

 Tay-Sachs disease 383
 TEMPO (2,2,6,6, tetramethylpiperidine-1-oxyl)
 292
 fluidity of human membranes 293

 Thermogenesis 265
 mechanism 267
 Thermoregulation 265
 Thrombin 31
 Thyroid hormone 268
 TLCK (N-tosyl-L-lysine chloromethyl ketone)
 88
 Trifluoperazine 88
 Trolox 91
 Tumor promotion 89
 activation of protein kinase C 84
 Tyrosine kinase 32
 activated in human tumors 44

 Ubiquinone-cytochrome *c* oxidoreductase
 (complex III) 216
 Uncoupling protein 259, 266
 as dimer 267
 GDP binding 274
 latent form 272
 long-term regulation 272
 masking-unmasking 272
 mRNA-synthesis 275
 Unsaturated fatty acids 289

 V-fes 46
 V-src 46
 Viral oncogenes 14
 Vitamin C
 antioxidant, anticancer, anti-aging effects
 338
 Vitamin E 90, 338
 anticancer, anti-aging effects 338
 antioxidant role 90, 338
 differentiation in human neuroblastoma 90
 H₂O₂ production inhibition in human
 neutrophils 90
 in plasma 91
 platelet anti-aggregation agent 90

 X-linked adrenodystrophy 411

 Zellweger syndrome 411, 420